5AM Ventures’ Post

5AM Ventures reposted this

View organization page for Entrada Therapeutics, graphic

23,604 followers

Entrada Therapeutics reports preliminary data in healthy volunteers from Phase 1 ENTR-601-44-101 trial for Duchenne muscular dystrophy. Learn more here: https://lnkd.in/dMPZtt9a

  • A graphic with a photo of Dipal Doshi, Entrada’s Chief Executive Officer. There is a quote that reads, “Today marks an exciting and important milestone in our journey as we share data from the first clinical study in our Duchenne franchise. Our approach to Duchenne has always been clear, we are working to develop a safe and effective therapy that meets the changing needs of a growing child or young man. One where patients, families and their providers are in charge and can change dosing, or even start and pause therapy, based on their broader healthcare needs.”
Darren Nelson 🚀 (We're hiring)

Innovative Leadership in Life Sciences & Technology Talent Solutions: Founder & CEO of Recruits Lab & BioJobs Lab, Driving Organizational Success through Cutting-Edge Recruitment Strategies

2mo

Congratulations to Entrada Therapeutics on reporting preliminary data from the Phase 1 ENTR-601-44-101 trial for Duchenne muscular dystrophy. This is a promising step forward in the fight against DMD. Excited to see the continued progress and impact of your work.

Like
Reply
Kenneth Peist

VP, Intellectual Property at Dermavant Sciences

2mo

Congratulations, Dipal and the rest of the Entrada Team! Best of luck as you head into phase 2 studies.

Like
Reply
Kathryn Perry-Cockrill

ADMIN Construction/Engineering OSP Design Engineer at AT&T

1mo

This is so AWESOME‼️

Like
Reply
Ginne Davis

Bank Director at Community National Bank & Trust of Texas

2mo

Excellent news for the dmd community!

brian nicholoff

Advocate for Duchenne Muscular Dystrophy. volunteer for various charities. Class A life member of the PGA of America

2mo

Exciting times!

Like
Reply
See more comments

To view or add a comment, sign in

Explore topics